PL378555A1 - Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK - Google Patents

Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK

Info

Publication number
PL378555A1
PL378555A1 PL378555A PL37855504A PL378555A1 PL 378555 A1 PL378555 A1 PL 378555A1 PL 378555 A PL378555 A PL 378555A PL 37855504 A PL37855504 A PL 37855504A PL 378555 A1 PL378555 A1 PL 378555A1
Authority
PL
Poland
Prior art keywords
xanthine derivatives
sulfonamide substituted
substituted xanthine
pepck inhibitors
pepck
Prior art date
Application number
PL378555A
Other languages
English (en)
Inventor
Louise Helen Foley
Pete William Dunten
Nicholas John Silvester Huby
Sherrie Lynn Pietranico-Cole
Weiya Yun
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL378555A1 publication Critical patent/PL378555A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL378555A 2003-02-19 2004-02-12 Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK PL378555A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44856203P 2003-02-19 2003-02-19

Publications (1)

Publication Number Publication Date
PL378555A1 true PL378555A1 (pl) 2006-05-02

Family

ID=32908606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378555A PL378555A1 (pl) 2003-02-19 2004-02-12 Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK

Country Status (14)

Country Link
EP (1) EP1599477B1 (pl)
JP (1) JP2006515337A (pl)
KR (1) KR100728425B1 (pl)
CN (1) CN100361992C (pl)
AT (1) ATE385234T1 (pl)
AU (1) AU2004213124A1 (pl)
BR (1) BRPI0407695A (pl)
CA (1) CA2514472A1 (pl)
DE (1) DE602004011603T2 (pl)
ES (1) ES2298722T3 (pl)
MX (1) MXPA05008672A (pl)
PL (1) PL378555A1 (pl)
RU (1) RU2340613C2 (pl)
WO (1) WO2004074288A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TWI549947B (zh) * 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
BR0311760A (pt) * 2002-06-12 2005-03-29 Hoffmann La Roche Composto, pró-droga de um composto, processo para a preparação do composto, composições farmacêuticas que compreendem o mesmo, sua utilização e método de tratamento de diabetes do tipo 2

Also Published As

Publication number Publication date
WO2004074288A1 (en) 2004-09-02
DE602004011603T2 (de) 2009-01-29
ATE385234T1 (de) 2008-02-15
KR20050107432A (ko) 2005-11-11
MXPA05008672A (es) 2005-10-18
JP2006515337A (ja) 2006-05-25
EP1599477A1 (en) 2005-11-30
ES2298722T3 (es) 2008-05-16
RU2005128833A (ru) 2006-07-27
BRPI0407695A (pt) 2006-03-01
RU2340613C2 (ru) 2008-12-10
CN1751044A (zh) 2006-03-22
DE602004011603D1 (de) 2008-03-20
EP1599477B1 (en) 2008-01-30
KR100728425B1 (ko) 2007-06-13
CA2514472A1 (en) 2004-09-02
CN100361992C (zh) 2008-01-16
AU2004213124A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
PL378555A1 (pl) Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
CY1111410T1 (el) Αναστολεις τουμπουλινης
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
GB2392154B (en) Protein Kinase Inhibitors
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
DE60331187D1 (de) Kinaseinhibitoren
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
NO20025590D0 (no) Fenylglycin-derivater
HRP20060286T3 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
MXPA05009282A (es) Derivados de anilina sustituidos.
CA2487033A1 (en) Amide substituted xanthine derivatives with gluconeogenesis modulating activity
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler
WO2005053702A3 (en) Anti-inflammatory agents
SG171472A1 (en) Substituted aniline derivatives
DE60209354D1 (de) Hydroxamsäure-derivate
UA100002C2 (en) Normal;heading 1;heading 2;heading 3;PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)